Novartis Ag

Markus Furegati

Xiaodong Lin

Robert Lowell Simmons

Qingming Zhu

Guido Koch

Folkert Reck

Anthony Casarez

Flavio Ossola

Philipp Holzer

Joseph Schoepfer

Niko Schmiedeberg

Frédéric Zecri

Vincent Bordas

Ross Strang

Jürgen Hans-Hermann Hinrichs

Simone Plattner

Jvan Brun

Jacques Hamon

Henrik Möbitz

Fatma Limam

Sandro Nocito

The present invention provides a compound, or a pharmaceutically acceptable salt thereof, of formula (I): wherein R, R, R, R, R, R, R, y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention.

Bicyclic compounds and their uses

This invention pertains generally to compounds of Formula (A), as further described herein, which act as beta-lactamase inhibitors, and salts, crystalline forms and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds in combination with a beta-lactam antibiotic to treat infections caused by Gram-negative bacteria, including drug-resistant strains. 

Beta-lactamase inhibitors

This invention pertains generally to compounds of Formula (A), as further described herein, which act as beta-lactamase inhibitors, and salts, crystalline forms and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds in combination with a beta-lactam antibiotic to treat infections caused by Gram-negative bacteria, including drug-resistant strains.

Growing community of inventors

Basel, Switzerland

Markus Furegati